“Trump announced the next in a long line of vanity projects: TrumpRX, a forthcoming, federally branded website where Pfizer sells steeply discounted drugs in exchange for a three-year exemption from his proposed 100 percent tariffs on imported pharmaceuticals. Imagine a strip mall furniture store with a permanent, flashy 70-percent-off sale, masking the fact that prices were inflated in the first place. TrumpRx, slated to launch in early 2026, is no different—a government-run platform that promises savings while hiding costs.
…
TrumpRx isn’t healthcare reform or even a program in any real sense. It’s a carve-out for one company. Under the agreement, Pfizer will list a large share of its primary care and select specialty drugs at deep discounts on a federal site that redirects patients to Pfizer’s direct-to-consumer checkout.
…
The savings are shaky because that money has to come from somewhere. Part of it, certainly, is just the market advantage of being exempted from a 100 percent tax that all your competitors are forced to pay. Any savings beyond that will be carved out of something else—less research, higher prices on other drugs, or hidden costs buried elsewhere in the system.
And for most people, the ‘discounts’ aren’t really discounts. Roughly 90 percent of Americans are insured, and their co-pays are almost always cheaper than TrumpRx’s cash prices. Medicaid patients already get the steepest rebates—more than 60 percent off by law—so TrumpRx adds little there. That leaves the approximately 27 million uninsured Americans.
But even for the uninsured, the math falls apart: A $6,000 arthritis drug at “half price” is still $3,000 in cash, a stretch on any budget. Eucrisa at $162 on TrumpRx beats few insurance copays. And $499/month for Wegovy (semaglutide) on TrumpRx compares poorly to the $25 many insured patients now pay. And all of this bypasses the way Americans actually get prescriptions. CVS, Walgreens, and the rest are cut out entirely, replaced by a federally branded coupon pop-up that punts you to a manufacturer’s checkout page. TrumpRx looks like a deal, but in practice, it helps almost no one.”
“The Food and Drug Administration plans to approve a new use for the generic drug leucovorin in the coming weeks to treat kids with “cerebral folate deficiency and autistic symptoms,” according to a POLITICO Magazine opinion piece by federal health leaders published on Monday.
The officials — FDA Commissioner Marty Makary, National Institutes for Health Director Jay Bhattacharya and Centers for Medicare and Medicaid Services Administrator Mehmet Oz — pointed to research they say suggests leucovorin, also known as folinic acid, may help children who are deficient in folate, a vitamin. They said there was evidence leucovorin, which is currently used to treat cancer and anemia patients, can help children with autism improve their verbal communication. But they emphasized in the opinion piece that the drug “is not a cure for autism.”
While scientists say leucovorin, a form of vitamin B, could be promising for a subset of autism patients, they cautioned that the current data is limited and the drug needs more research.”
“What began as an initiative to improve seismic safety and veteran care now serves as a case study in bureaucratic drift. But this type of administrative breakdown is nothing new; the V.A. has long struggled to manage large capital projects and follow through on institutional commitments. From the Phoenix wait-time scandal in 2014—where staff falsified records to hide long delays in veteran care—to the more recent, failed $16 billion rollout of its Electronic Health Records (EHR) system, which was plagued by cost overruns and usability issues, the agency has a well-documented history of dysfunction.
The OIG report calls on the V.A. to reevaluate whether the project should continue. While that’s a difficult call after spending almost half a billion dollars (as of February 2025), it is very clearly a necessary step if the wasteful project is to be shut down. The center’s board of directors might think so too; it did not prioritize the ambulatory care facility in its FY 2026 budget request, and has been indecisive on how to proceed with future budget requests necessary to finance the project.
These actions, along with the implementation of updated contract guidelines in May and the call for a full departmental review in July, might suggest the V.A. finally recognizes that it has serious problems. However, until systemic accountability becomes ingrained in the V.A., boondoggles like the one in Palo Alto will continue at the expense of taxpayers and veterans’ health.”
“During the Biden administration’s four years, the CDC recorded a total of 527 cases. In just the first seven months of the Trump administration, there have been 1,408 cases with 176 hospitalizations and three deaths. That’s a 267 percent increase over the Biden administration’s entire toll. Instead of immediately recommending measles vaccines at the beginning of the outbreak, RFK Jr. initially advised giving vitamin A to children.
…
The CDC’s manifold failures during the COVID-19 pandemic made it clear that it needs drastic reform and a return to its roots as an agency focused on fighting infectious epidemic disease. This evidently is not the sort of reform that RFK Jr. intends. Firing Monarez may not be “weaponizing public health,” but it sure looks a lot like gutting it.”
“Pharmacists’ authority to vaccinate individuals varies across state lines. In some places, it’s dependent upon a federal advisory process that Health Secretary Robert F. Kennedy Jr. has upended.
At the same time, the Food and Drug Administration has signaled that it will only approve updated Covid vaccines for individuals 65 and older and for younger people considered to be at high risk for severe disease. People, regardless of where they live, may need to prove that they need the shot.
…
If the FDA narrows eligibility, people between 6 months and 65 years old who want a Covid vaccine this fall likely will have to navigate some roadblocks.
They, or their parents, may need to convince pharmacies and doctors that they have at least one of the underlying conditions that the FDA has suggested makes them eligible for a dose. The list includes asthma, diabetes, cancer, mood disorders and obesity. It’s unclear at this point what would serve as adequate proof.
…
Further complicating vaccination efforts for children this year: the FDA may pull Covid vaccine-maker Pfizer’s emergency use authorization for its shots for children under 5.”
The big city libs want to fund rural hospitals in flyover country. Trump does not.
“President Donald Trump pressed Congress in July to pass his big tax and spending law, which slashed more than $1 trillion from health care programs and could lead to an estimated 11.8 million people losing their health insurance. It also included cuts to what’s known as the provider tax, which nearly all states use to increase Medicaid payments to hospitals, in part to help them fund services in rural communities where providing care may not otherwise be financially possible.
By one estimate, the law’s tax cuts could force more than 300 rural hospitals to close. In Erwin, Tennessee, it may mean Unicoi Hospital never reopens, leaving the county without any hospitals or emergency rooms.”